Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents

Apoptosis

Volumn 18, Issue 7, 2013, Pages 836-850

  Bertrand, Julian ^a   Liagre, Bertrand ^a   Ghezali, Lamia ^a   Beneytout, Jean Louis ^a   Leger, David Yannick ^a  

^a UNIVERSITÉ DE LIMOGES   (France)

Author keywords

Akt; Apoptosis; Cyclooxygenase 2; Erythroleukemia; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME REGULATION; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; ARSENICALS; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; ETOPOSIDE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; OXIDES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAUROSPORINE;

EID: 84878743076     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0825-7     Document Type: Article

References (56)

1. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182
2. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181-193
3. Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279-286
4. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1-20
5. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102
6. Bernard MP, Bancos S, Sime PJ, Phipps RP (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14:2051-2060
7. Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML (2009) Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30:2005-2013
8. Zheng J, Chen S, Jiang L, You Y, Wu D, Zhou Y (2011) Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol 87:486-493
9. Santos FP, Bueso-Ramos CE, Ravandi F (2010) Acute erythroleukemia: diagnosis and management. Expert Rev Hematol 3:705-718
10. Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M (2001) Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 37:1570-1578
11. Subhashini J, Mahipal SV, Reddanna P (2005) Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224:31-43
12. Cervi D, Klement G, Stempak D, Baruchel S, Koki A, Ben-David Y (2005) Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin Cancer Res 11:712-719
13. Moalic S, Liagre B, Corbière C, Bianchi A, Dauça M, Bordji K, Beneytout JL (2001) A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett 506:225-230
14. Liagre B, Vergne-Salle P, Corbiere C, Charissoux JL, Beneytout JL (2004) Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression. Arthritis Res Ther 6:373-383
15. Corbiere C, Liagre B, Terro F, Beneytout JL (2004) Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res 14:188-196
16. Leger DY, Liagre B, Corbiere C, Cook-Moreau J, Beneytout JL (2004) Diosgenin induces cell cycle arrest and apoptosis in HEL cells with increase in intracellular calcium level, activation of cPLA2 and COX-2 overexpression. Int J Oncol 25:555-562
17. Liagre B, Bertrand J, Leger DY, Beneytout JL (2005) Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding. Int J Mol Med 16:1095-1101
18. Cailleteau C, Liagre B, Battu S, Jayat-Vignoles C, Beneytout JL (2008) Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells. Anal Biochem 380:26-34
19. Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, Damodaran C (2009) Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer 125:961-967
20. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20:5010-5018
21. Li CJ, Chang JK, Wang GJ, Ho ML (2011) Constitutively expressed COX-2 in osteoblasts positively regulates Akt signal transduction via suppression of PTEN activity. Bone 48:286-297
22. Shimada K, Anai S, Marco DA, Fujimoto K, Konishi N (2011) Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival. BMC Urol 11:8
23. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501
24. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K (2001) Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551
25. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJ (2006) What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119:2247-2254
26. Ryan EP, Pollock SJ, Kaur K, Felgar RE, Bernstein SH, Chiorazzi N, Phipps RP (2006) Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 120:76-90
27. Raju J, Patlolla JM, Swamy MV, Rao CV (2004) Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomarkers Prev 13:1392-1398
28. Raju J, Bird RP (2007) Diosgenin, a naturally occurring steroid saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells. Cancer Lett 255:194-204
29. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G (2010) Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 292:197-207
30. Lepage C, Léger DY, Bertrand J, Martin F, Beneytout JL, Liagre B (2011) Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett 301:193-202
31. Shishodia S, Aggarwal BB (2006) Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene 25:1463-1473
32. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
33. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676
34. Thompson JE, Thompson CB (2004) Putting the rap on Akt. J Clin Oncol 22:4217-4226
35. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L (2007) Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14:2009-2023
36. Johnson GE, Ivanov VN, Hei TK (2008) Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 13:790-802
37. Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S (2005) Rapamycin and UCN-01 synergistically induced apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4:457-470
38. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28:3866-3871
39. Kolitz JE, George SL, Dodge RK et al (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9,621. J Clin Oncol 22:4290-4301
40. Harousseau JL, Martinelli G, Jedrzejczak WW et al (2009) A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114:1166-1173
41. Pan X, Wang C, Wang F, Li P, Hu Z, Shan Y, Zhang J (2011) Development of 5-fluorouracil derivatives as anticancer agents. Curr Med Chem 18:4538-4556
42. Leger DY, Liagre B, Beneytout JL (2006) Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Apoptosis 11:1747-1760
43. Grandage VL, Gale RE, Linch DC, Khwaja A (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19:586-594
44. Broxterman HJ, Gotink KJ, Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12:114-126
45. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB (2005) Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105:4477-4483
46. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22:686-707
47. Polak R, Buitenhuis M (2012) The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119:911-923
48. Sheng H, Shao J, Washington MK, DuBois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081
49. Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF (2004) Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676-1685
50. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S (2007) Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 120:796-805
51. Covey TM, Edes K, Fitzpatrick FA (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26:5784-5792
52. Hill R, Li Y, Tran LM, Dry S, Hargan Calvopina J, Garcia AJ, Kim C, Wang Y, Donahue TR, Herschman HR, Wu H (2012) Cell intrinsic role of Cox-2 in pancreatic cancer development. Mol Cancer Ther 11:2127-2137
53. Zhou P, Qian L, Chou T, Iadecola C (2008) Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 29:543-551
54. Pan MR, Hou MF, Chang HC, Hung WC (2008) Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 283:11155-11163
55. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA (2009) Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 23:1291-1305
56. George RJ, Sturmoski MA, Anant S, Houchen CW (2007) EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83:112-120